VOLUME 23 (cid:1) NUMBER 6 (cid:1) FEBRUARY 20 2005
J OURNAL OF C LINICAL O NCOLOGY O R I G I N A L R E P O R T
Irinotecan Plus Oxaliplatin and Leucovorin-Modulated
Fluorouracil in Advanced Pancreatic Cancer—A Groupe
Tumeurs Digestives of the Fédération Nationale des
Centres de Lutte Contre le Cancer Study
ThierryConroy,BernardPaillot,EricFran¸cois,RolandBugat,Jacques-HenriJacob,UlrichStein,
SalvadorNasca,Jean-PhilippeMetges,OlivierRixe,PierreMichel,EmmanuelleMagherini,AlietteHua,
andGaelDeplanque
FromCentreAlexisVautrin,Nancy;
A B S T R A C T
UniversityHospital,Rouen;Centre
AntoineLacassagne,Nice;Centre
Purpose
ClaudiusRegaud,Toulouse;Centre
Toevaluateresponserateandtoxicityofirinotecanandoxaliplatinplusfluorouracil(FU)and
Franc¸oisBaclesse,Caen;University
HospitalJeanMinjoz,Besanc¸on; leucovorin(Folfirinox)inadvancedpancreaticadenocarcinoma(APA).
InstitutJeanGodinot,Reims;University
PatientsandMethods
Hospital,Brest;CliniqueClaude
Chemotherapy-naive patients with histologically proven APA and bidimensionally measur-
Bernard,Metz;andLaboratoireAventis,
Paris,France. ablediseaseweretreatedwithFolfirinoxtherapyevery2weeks,whichcomprisedoxaliplatin
85mg/m2andirinotecan180mg/m2plusleucovorin400mg/m2followedbybolusFU400
SubmittedJune7,2004;accepted
mg/m2onday1,thenFU2,400mg/m2asa46-hourcontinuousinfusion.Qualityoflife(QOL)
November3,2004.
wasassessedusingEuropeanOrganisationforResearchandTreatmentofCancerQualityof
Presentedinpartatthe39thAnnual
LifeQuestionnaireC30(EORTCQLQ-C30).
MeetingoftheAmericanSocietyof
ClinicalOncology,Chicago,IL, Results
May31-June3,2003. Forty-sevenpatientswereentered,and46receivedtreatment.Thirty-fivepatients(76%)had
Authors’disclosuresofpotentialcon- metastaticdisease.Atotalof356cyclesweredelivered,withamedianofeightcyclesper
flictsofinterestarefoundattheendof patient (range, one to 24 cycles). All patients were assessable for safety. No toxic death
thisarticle.
occurred.Grade3to4neutropeniaoccurredin52%ofpatients,includingtwopatientswith
AddressreprintrequeststoThierry febrile neutropenia. Other relevant toxicities included grade 3 to 4 nausea (20%), vomiting
Conroy,MD,DepartmentofMedical (17%), and diarrhea (17%) and grade 3 neuropathy (15%; Levi’s scale). The confirmed
Oncology,CentreAlexisVautrin,54511
responseratewas26%(95%CI,13%to39%),including4%completeresponses.Median
Vandoeuvre-lès-NancyCedex,France;
time to progression was 8.2 months (95% CI, 5.3 to 11.6 months), and median overall
e-mail:t.conroy@nancy.fnclcc.fr.
survival was 10.2 months (95% CI, 8.1 to 14.4 months). Between baseline and end of
©2005byAmericanSocietyofClinical
treatment,patientshadimprovementinallfunctionalscalesoftheEORTCQLQ-C30,except
Oncology
cognitivefunctioning.RespondershadmajorimprovementinglobalQOL.
0732-183X/05/2306-1228/$20.00
Conclusion
DOI:10.1200/JCO.2005.06.050
Withagoodsafetyprofile,apromisingresponserate,andanimprovementinQOL,Folfirinox
willbefurtherassessedinaphaseIIItrial.
JClinOncol23:1228-1236.©2005byAmericanSocietyofClinicalOncology
creatic cancers and the lack of effective sys-
INTRODUCTION
temic therapies, only 1% to 4% of patients
Pancreaticcancerranksasthefourthleading withadenocarcinomaofthepancreaswillbe
causeofcancerdeathsintheWesternworld. alive5yearsafterdiagnosis.1,3Advancedpan-
There are an estimated 30,000 deaths in the creaticadenocarcinoma(APA)remainsanin-
UnitedStates1and50,000deathsperyearin curable disease with few good treatment
Europe.2Becauseoftheaggressivenessofpan- options. However, two randomized trials
1228
Downloaded from jco.ascopubs.org on April 23, 2015. For personal use only. No other uses without permission.
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
FolfirinoxinAdvancedPancreaticCancer
demonstratedthatchemotherapyimprovesbothsurvivaland disease,atleastonebidimensionallymeasurablelesionaccording
quality of life (QOL) compared with best supportive care toWHOcriteria,33nopreviouschemotherapyorradiotherapy,an
(BSC).4,5Arandomizedtrialcomparinggemcitabinewith30- agebetween18and70years,aWHOperformancestatus(PS)less
than2,andadequatebonemarrow,liver(totalbilirubin(cid:1)1.5(cid:1)
minute infusion fluorouracil (FU) demonstrated a modest
theupperlimitsofnormal[ULN],ASTandALT(cid:1)3(cid:1)UNL,and
significantsurvivaladvantageforthegemcitabinegroup.6Sev-
alkalinephosphatases(cid:2)3(cid:1)ULNor(cid:2)5(cid:1)ULNincaseofliver
eral attempts at developing more efficacious gemcitabine- involvement), and renal function (creatinine (cid:2) 130 (cid:2)mol/L).
basedregimenshavebeencarriedout,butdespiteencouraging Surgicalunresectabilitywasdefinedbylaparotomyorbymultidis-
resultsfromphaseIItrials,randomizedstudiestodatehave ciplinaryconsultationlookingatradiologiccriteriaasextrapan-
notshownasurvivalbenefitforcombinationchemotherapy creaticdiseaseorceliacorsuperiormesentericarteryinvolvement.
overgemcitabinealone.7-15Therefore,neweffectiveandwell- Writteninformedconsentwasrequired,andtheethicalcommit-
toleratedregimensarewarranted. tee approved the study. Patients with CNS metastases, second
malignancies,andahistoryofchronicdiarrhea,anginapectoris,
Irinotecan, a camptothecin analog, has been demon-
National Cancer Institute Common Toxicity Criteria grade
stratedtohaveahighergrowthinhibitoryeffectagainstcul-
greater than 1 peripheral neuropathy, or psychiatric disorders
turedpancreaticadenocarcinomathancisplatin,mitomycin,
wereexcluded.
andFU.16Preclinicalstudieshaveindicatedasynergywhen
irinotecanprecedesFU-leucovorinexposure.17-19Otherstud- Chemotherapy
ieshaveshownhighactivityofirinotecanonpancreatictumor
Folfirinoxconsistedofoxaliplatin85mg/m2dilutedin5%
cells in culture and in xenografts.20,21 Irinotecan has been dextroseadministeredasa2-hourintravenousinfusionfollowed
byirinotecan180mg/m2administeredasa90-minuteinfusionin
investigated as a single agent in patients with nonpre-
dextrose 5% 500 mL or normal saline 1 hour after the end of
treated APA, producing response rates from 9% to
oxaliplatininfusion.ThesimplifiedLV5FUregimenwasadminis-
27%.22-24Someactivityassecond-linechemotherapyhas
tered after the irinotecan infusion as follows: leucovorin 400
alsobeenreported.25,26 mg/m2over2hoursfollowedbyFU400mg/m2bolus,thenFU
Oxaliplatin,aplatinum-baseddrug,alsoinhibitspan- 2,400mg/m2wasadministeredasa46-hourcontinuousinfusion.
creatic tumor cell lines.27 When used as a single agent, Treatmentcycleswererepeatedevery2weeks.
Antiemeticprophylaxiswaslefttoinvestigator’sdiscretion.
oxaliplatin has minimal activity against APA, but a 10%
Incaseofseverecholinergicsyndrome,preventivetreatmentwith
response rate has been described when it was used with
atropine(0.25mgsubcutaneously)wastobeadministeredatall
FU.28 In vitro, synergistic activity has been described be-
subsequentcycles.Ifpatientsexperienceddelayeddiarrhea,early
tweenirinotecanandoxaliplatin.29,30Differencesinmech-
high-doseloperamidewasprescribedaccordingtospecificguide-
anism of action of oxaliplatin and irinotecan, combined lines,andifdiarrheapersistedmorethan48hours,prophylactic
with the demonstrated antitumor activity of each agent, oralfluoroquinoloneswereadministered.Incaseofsevereneutro-
suggestthatcoadministrationofoxaliplatinandirinotecan peniaand/ornorecoverytogradelessthan1atday14,further
cycles could be administered with a granulocyte colony-
topatientswithAPAmayprovideclinicaloutcomessuperior
stimulatingfactor(G-CSF).
tothoseobtainedwitheitherdrugadministeredalone.Fur-
Patientswereassessedfortoxicitybeforeeachcycle.Chemo-
thermore,withtheexceptionofmyelosuppressionanddiar-
therapywasdelayeduntilrecoveryifneutrophilswerelessthan
rhea,thetwodrugshavenooverlappingclinicaltoxicity. 1.5(cid:1)109/Lorplateletswerelessthan100(cid:1)109/L.Dosesadjust-
OnepreviousphaseItrial31evaluatedatripletcombi- mentsweremadeaccordingtonadirvaluesandtimeofrecoveryto
nation of leucovorin plus bolus and continuous-infusion agrade(cid:1)1.Dosesreductionswerealsorecommendedincaseof
FU (LV5FU),32 irinotecan, and oxaliplatin. The recom- grade3to4diarrhea,stomatitis,handandfootsyndrome,and
mended doses were oxaliplatin 85 mg/m2, irinotecan 180 vomitingand/orincaseofgrade2peripheralneuropathy.Forany
other nonhematologic toxicity that occurred with grade (cid:3) 2, a
mg/m2,andfulldosesofsimplifiedLV5FU.Offivepatients
maximumdelayoftreatmentof2weekswasallowedtoattempt
with APA, one complete response (CR) and one partial recoverytograde(cid:1)1.Oncethedosewasdecreased,re-escalation
response(PR)wereobserved.Onthebasisoftheseencour- wasnotpermitted.Patientswentoffstudyiftheyrequiredmore
agingresults,amulticenterphaseIIstudyoftheoxaliplatin thantwodosereductions.
and irinotecan plus LV5FU combination (Folfirinox) was Treatment was continued until disease progression, unac-
conducted by the Gastrointestinal Tumor Group of the ceptable toxicity, or patient refusal. Twelve cycles were recom-
mendedinrespondingpatients,andpatientswereobservedevery
French Anticancer Centers. The main objectives were to
3monthsuntildeathorcutoffdate.
assesstheefficacyandsafetyoftheFolfirinoxcombination
asfirst-linetreatmentinpatientswithAPA. EfficacyAssessment
Theprimaryefficacyendpointwasresponserate,whichwas
defined as the sum of CR and PR assessed according to WHO
PATIENTSANDMETHODS
criteria.33 CR was defined as the complete disappearance of all
assessabledisease,andPRwasdefinedasadecreaseofatleast50%
PatientsSelection ofthesumoftheproductsofthediametersofmeasurablelesions.
Eligiblepatientswererequiredtohavehistologicallyorcyto- Responseshadtobeconfirmedbyrepeatassessmentsperformed
logicallyprovenAPA,unresectablelocallyadvancedormetastatic nolessthan4weeksafterthecriteriaforresponsewerefirstmet.
www.jco.org 1229
Downloaded from jco.ascopubs.org on April 23, 2015. For personal use only. No other uses without permission.
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
Conroyetal
Stable disease was defined as a decrease of less than 50% or an tics of the 46 treated patients are listed in Table 1. The
increaseoflessthan25%inmeasurablelesions,andprogressive medianagewas56years(range,40to69years),and76%of
diseasewasdefinedasanincreaseofatleast25%inmeasurable
patientshadstageIVbdiseaseatdiagnosis.Among11pa-
lesionsortheappearanceofnewmalignantlesion(s).Computed
tientswithlocallyadvanceddisease,twopatientshadceliac
tomography scan imaging was performed at baseline and then
artery involvement, one patient had local recurrence, and
every6weeksuntildiseaseprogression.Patientswhowerewith-
drawn from study before the first evaluation were classified as eightpatientshadunresectabletumorassessedduringex-
havingexperiencedtreatmentfailure.Allcomputedtomography plorative laparotomy. Thirty-four patients (74%) had an
scans were reviewed by an external response review committee impairedPS,and39patients(85%)weresufferingatleast
(ERRC),whichwasapaneloftwoindependentradiologistsnot fromonedisease-relatedsymptomatstudyentry.
involvedinthestudy.Secondaryefficacyendpointsincludedthe
durationofresponseandstabilization,timetoprogression,and Study Treatment and Drug Delivery
overallsurvival.Timetoprogressionwascalculatedfromthestart A total of 356 cycles were completed (median, eight
oftreatmenttothefirstdayofprogression.Survivallastedfrom cyclesperpatient;range,oneto24cycles).Dosesreductions
thedateofinclusionuntildeath. wererequiredin50cycles(14%),andthemainreasonsfor
SafetyAssessment dose reduction were hematologic toxicity, neurotoxicity,
Patientswhoreceivedatleastoneinfusionwereassessablefor
anddiarrhea(Table2).Shorttreatmentdelays((cid:2)7days)
safety.Forhematologicandbiologicparameters,atleastonemea- occurredin48cycles(13%),andlongerdelays((cid:3)7days)
sure per cycle was required. Toxic effects (except paresthesias) occurred in 66 cycles (19%). Those delays were mainly a
weregradedusingtheNationalCancerInstituteCommonToxic-
ity Criteria version 1.0. Peripheral sensitive neuropathy was
gradedaccordingtoLevi’sspecificgrading.34
Table1.CharacteristicsofTreatedPatients
QOLandClinicalBenefitAssessment
QOLwasassessedusingtheEuropeanOrganisationforRe- No.of
Patients %
searchandTreatmentofCancerQualityofLifeQuestionnaireC30
(EORTCQLQ-C30,version3.0).TheEORTCQLQ-C30isa30- Sex
itemquestionnaireincludingfivefunctionalscales,threesymp- Male 30 65
tom scales, one QOL scale, and six single items on common Female 16 35
symptoms.35 The EORTC QLQ-C30 questionnaire was distrib- Age,years
Median 56
utedtothepatientsbeforeeachcycleandattheendofthetreat-
Range 40-69
ment. Questionnaires were scored according to the EORTC
WHOperformancestatus
instructions.36 Baseline and last available questionnaires were
0 12 26
compared.Theprimaryobjectivewastoanalyzechangesinglobal
1 34 74
QOL, and secondary objectives were to describe changes in fa-
Diseasestage
tigue, pain, physical functioning, and emotional functioning.
StageIII/IVa 11 24
Thesescaleswerechosenbecausetheyarethemostdeterioratedin
StageIVb 35 76
APApatientsaccordingtotheEORTCreferencevaluesmanual.37
Priorsurgery
Clinicalbenefitresponsewasevaluatedaccordingtoassessmentof None 23 50
consumptionofpain-relievingdrugs,weighttrends,orevolution Curativeresection 2 4
ofastheniaoranorexia. Explorativelaparotomy 9 20
Palliativesurgery 12 26
StatisticalConsiderations
No.ofsitesinvolved(cid:1)
AccordingtoaSimontwo-stagephaseIIoptimaldesign38for
1 6 13
agoalof25%trueresponseratewithan(cid:4)and(cid:5)errorprobability
2 19 41
of.05and.20,respectively,anaccrualofatleast40eligiblepatients
3 13 28
assessableforresponsewasplanned.Assumingthat15%ofpa- (cid:3)4 8 17
tientswouldbeinassessable,46patientsneededtobeincluded.An Diseaselocalization
early termination of the study was required if less than three Pancreas 45 98
responses were observed in the first 22 patients. Otherwise, re- Liver 28 61
cruitment continued. The 95% CI for response was calculated. Lymphnodes 24 52
Time-relatedparameters,includingmedianfollow-uptime,were Peritoneum 11 24
analyzedusingtheKaplan-Meiermethod.39,40 Lung 4 9
Other† 2 4
Signsandsymptoms
RESULTS Weightloss(cid:3)5% 30 65
Disease-relatedpain 32 70
Asthenia 16 35
Patient Characteristics
Anorexia 16 35
FromJune2000toJune2002,47patientswereenrolled
(cid:1)Includingabdominallymphnodes.
at nine French centers. One patient was never treated be- †Onepatientwithovarianmetastasesandonewithascitis.
causeofsuddenonsetoficterus.Thebaselinecharacteris-
1230 JOURNALOFCLINICALONCOLOGY
Downloaded from jco.ascopubs.org on April 23, 2015. For personal use only. No other uses without permission.
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
FolfirinoxinAdvancedPancreaticCancer
resultofatleastonehematologictoxicity(76cycles,67%).
Table2.DrugDelivery
In 25 cycles (22%), delays were unrelated to study treat-
DrugDelivery Values
ment.Thedeliveredrelativedose-intensityperpatientwas
TotalNo.ofcycles 356 82%foroxaliplatin,84%foririnotecan,and83%forFU.
No.ofcyclesperpatient
Median 8 Objective Response and Survival
Range 1-24
Response rate was evaluated in all treated patients.
Relativedose-intensityperpatient,%
Oxaliplatin Afterthefirst22assessablepatientsweretreated,fourcon-
Median 82 firmedobjectiveresponseswereobservedand,thus,accrual
95%CI 35to103
couldcontinue.OverallresultsarelistedinTable3.Twelve
Irinotecan
PRs(26%)and18stabilizations(39%)wereobservedbythe
Median 84
95%CI 38to101 investigators, resulting in an overall response rate of 26%
Fluorouracilbolus (95%CI,13%to39%).Three(27.3%)of11patientswith
Median 83
local APA and nine of 35 patients with metastatic disease
95%CI 6to101
Continuousfluorouracil achievedaconfirmedresponse.Thiswasconfirmedbythe
Median 83 ERRC,withtwoCRs(4%),10PRs(22%),and16patients
95%CI 40to101
withstabledisease(35%).Withamedianfollow-upof33
Cycleswithdosereductions
No. 50 months, the median response duration was 10.4 months
% 14 (95%CI,9.0to15.2months),andmedianprogression-free
Responsibledrugfordosereductions
Oxaliplatin
No.ofcycles 24
% 7
Irinotecan
Table3.EfficacyResults(N(cid:4)46)
No.ofcycles 22 Assessedbyan Assessedby
% 6 Independent the
Fluorouracil Response Review Investigators
No.ofcycles 21
Objectiveresponserate
% 6
No. 12 12
Mainreasonforreduction
Hematologictoxicity % 26 26
Oxaliplatin 95%CI,% 13to39 13to39
No.ofcycles 9 Responseduration,months
% 38 Median 9.3 10.4
Irinotecan 95%CI 8.2to13.6 9.0to15.2
No.ofcycles 8 Timetoprogression,months
% 36 Median 8.2 5.6
Fluorouracil 95%CI 5.3to11.6 3.4to9.0
No.ofcycles 16
Survival,months
% 76
Overall
Neurotoxicity
Median 10.2
Oxaliplatin
95%CI 8.1to14.4
No.ofcycles 12
% 50 Metastaticpatients
Diarrhea Median 9.5
Irinotecan 95%CI 5.6to13.7
No.ofcycles 9 Locallyadvancedpatients
% 41 Median 15.7
Fluorouracil 95%CI 8.9to43
No.ofcycles 1 Symptombenefit
% 5 Increaseofweight,n(cid:4)46
Delayedcycles
No. 12
Total
% 26
No. 114
Decreaseinanorexia,n(cid:4)27
% 32
Becauseofhematologictoxicity No. 8
No. 76 % 30
% 67 Decreaseinfatigue,n(cid:4)19
Delayedbetween4and7days No. 4
No. 48 % 21
% 13 Morethan50%decreaseinanalgesic
Delayedmorethan7days consumption,n(cid:4)39
No. 66 No. 9
% 19 % 23
www.jco.org 1231
Downloaded from jco.ascopubs.org on April 23, 2015. For personal use only. No other uses without permission.
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
Conroyetal
survival(PFS)was5.6months(95%CI,3.4to9.0months)
Table4.MainGrade3to4ToxicitiesRelatedtoStudyTreatment
according to the investigators. According to the ERRC,
medianresponsedurationwas9.3months(95%CI,8.2to PerPatient PerCycle
(N(cid:4)46) (N(cid:4)356)
13.6months),medianPFSwas8.2months(95%CI,5.3to
Grade3 Grade4 Grade3 Grade4
11.6months),andmediandurationofstablediseasewas7.5
Toxicity No. % No. % No. % No. %
months (95% CI, 5.1 to 15.1 months). When tumor pro-
gressed, 31 patients (67%) received a second-line treat- Hematologictoxicities
ment,includinggemcitabine(n(cid:4)18),radiochemotherapy Neutropenia 16 35 8 17 54 15 24 7
Febrileneutropenia — — 2 4 — — 2 1
(n(cid:4)4),Folfiri(irinotecan,bolus-andcontinuous-infusion
Anemia 5 11 3 7 7 2 3 1
FU; n (cid:4) 3), gemcitabine and oxaliplatin (n (cid:4) 1), Folfox Thrombocytopenia 2 4 1 2 2 1 1 (cid:2)0.5
(oxaliplatin, bolus- and continuous-infusion FU; n (cid:4) 1), Mainnonhematologic
andFU-leucovorin(n(cid:4)1).Afterhavingstoppedchemo- toxicities
Diarrhea 7 15 1 2 11 3 1 (cid:2)0.5
therapy, three patients who responded to Folfirinox re-
Nausea 9 20 — — 9 3 — —
ceivedFolfirinoxagainwhentheyprogressed. Vomiting 8 17 — — 9 3 — —
Medianoverallsurvivalwas10.2months(95%CI,8.1 Asthenia 9 20 1 2 16 4 1 (cid:2)0.5
to14.4months);inmetastaticpatients,themedianoverall Peripheralneuropathy 7 15 NA NA 10 3 — —
Alopecia(cid:1)
survivalwas9.5months(95%CI,5.6to13.7months,andin
No. 9 NA
locallyadvancedpatients,itwas15.7months(95%CI,8.9
% 20 NA
to 43 months). The 1-year survival rate was 43% for the
(cid:1)Grade2.
wholegroup(Fig1).Sixpatients(includingthreepatients
with metastatic disease) are still alive, with a mean
follow-upof(cid:5)30months(range,(cid:5)26to(cid:5)33months).
respectively. Diarrhea led to hospitalization for four pa-
Safety tients. Thirteen percent and 15% of patients experienced
Alltreatedpatients(n(cid:4)46)wereassessableforsafety,
grades2and3peripheralneuropathy,respectively,leading
and no treatment-related deaths occurred. Grade 3 to 4 tostudydiscontinuationforsevenpatients(15%).
toxicitiesarelistedinTable4.Themostcommontoxicity
QOL
washematologic,with52%ofpatientsexperiencingagrade
Among all patients, 256 (65.8%) of a possible 389
3or4neutropeniain22%ofcycles.Grade4febrileneutro-
EORTC QLQ-C30 forms were completed. For eight pa-
peniaoccurredintwopatients(4%)withoutgrowthfactors
tients(17%),nobaselinequestionnairewasavailable.There
support.Overall,fourpatientsreceivedG-CSFfor12cycles.
wasnodifferencebetweentheoverallpopulationandthe38
Theothergrade3or4treatment-relatedhematologictox-
patientswhocompletedthebaselinequestionnairesregard-
icitieswereanemiaandthrombocytopenia,whichoccurred
ing sex ratio, PS, median age, and disease stage. Two pa-
in18%and6%ofpatients,respectively.
tientswhohadcompletedthebaselinequestionnairefailed
Nonhematologictoxicitiesofgrade3to4occurredin
tocompletefurtherforms.Patientswithobjectiveresponse
less than 5% of cycles. Grades 3 and 4 vomiting was ob-
and those with minor response (n (cid:4) 5) were classified as
servedin20%and17%ofpatients,respectively,andgrades
responders(n(cid:4)14)fortheQOLanalysisandwerecom-
3 and 4 asthenia occurred in 20% and 2% of patients,
paredtopatientswithstable(n(cid:4)12)orprogressivedisease
(n(cid:4)12).Medianscoresatbaselineandattheendofstudy
treatmentarelistedinTable5togetherwiththepercentage
ofpatientswith10pointsindegradationorimprovementof
eachscores.
Regarding the primary QOL end point, global QOL
scores deteriorated in 18.8% of the patients, and 37.5%
reportedamoderateimprovement((cid:3)10points).Ofnote,
the global QOL score was improved by 25 points in re-
sponders,amajorimprovementaccordingtothecriteriaof
Osobaetal.41ThescoresofthesecondaryQOLobjectivesof
fatigue,pain,andphysicalandemotionalfunctioningim-
provedbymoreof10pointsin36%,53%,21%,and36%of
the patients, respectively. Changes in global QOL scores
wereassociatedwithtreatmentresponse(P(cid:4).003).Global
QOL scores at baseline were not predictive of treatment
Fig1.Overallsurvivalinalltreatedpatients.
outcome(P(cid:4).54).
1232 JOURNALOFCLINICALONCOLOGY
Downloaded from jco.ascopubs.org on April 23, 2015. For personal use only. No other uses without permission.
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
FolfirinoxinAdvancedPancreaticCancer
Table5.ChangesinQOLScoresFromBaselinetotheLastKnownValues
EndofTreatment
BaselineScores Scores Overall MR(cid:5)CR(cid:5)PR
(n(cid:4)38) (n(cid:4)36) (n(cid:4)36) (n(cid:4)13)
%ofPatients %ofPatients %ofPatients %ofPatients
With10Points With10Points With10Points With10Points
DomainsofEORTCQLQ-C30 Median Range Median Range Degradation Improvement Degradation Improvement
Functionalscales(cid:1)
GlobalQOL 58.3 16.7-100 66.7 0-100 18.8 37.5 0 66.7
Physical 86.7 6.7-100 90 33-100 21.2 21.2 15.4 53.8
Role 66.7 0-100 83.3 0-100 31.3 40.6 23.1 69.2
Cognitive 100 33.3-100 83.3 50-100 30.3 27.3 30.8 38.5
Emotional 70.8 8.3-100 75.0 42-100 12.1 36.4 0 61.5
Social 66.7 0-100 100 0-100 21.2 48.5 7.7 61.5
Symptomscales†
Fatigue 33.3 0-100 33.3 0-100 36.4 36.4 15.4 69.2
Nauseaandvomiting 0.0 0-100 0.0 0-100 24.2 33.3 7.7 46.2
Pain 33.3 0-100 16.7 0-100 15.6 53.1 8.3 75.0
Singleitems†
Dyspnea 33.3 0-100 0.0 0-66.7 9.1 33.3 0 61.5
Insomnia 33.3 0-100 33.3 0-100 18.2 36.4 7.7 69.2
Appetiteloss 33.3 0-100 0.0 0-100 12.1 51.5 0 61.5
Constipation 33.3 0-100 0.0 0-100 6.1 51.5 7.7 61.5
Diarrhea 0.0 0-100 33.3 0-100 34.4 21.9 16.7 41.7
Abbreviations:QOL,qualityoflife;EORTCQLQ-C30,EuropeanOrganisationforResearchandTreatmentofCancerQualityofLifeQuestionnaireC30;MR,
minorresponse;CR,completeresponse;PR,partialresponse.
(cid:1)Highscore(cid:4)highleveloffunctioning.
†Highscore(cid:4)highlevelofsymptoms.
Medianscoresofallfunctionalscalesimprovedduring thisselectedpopulation,Folfirinoxregimenseemspromis-
treatment, except cognitive functioning. Most symptoms ingandhasafavorabletoleranceprofile.Despiteahighrate
such as pain, dyspnea, appetite loss, and constipation de- of grade 3 to 4 neutropenia (52% of patients, 22% per
creasedundertreatmentexceptdiarrhea.Fatigueandnau- cycle),onlytwocasesoffebrileneutropeniaoccurred.He-
seawereunchanged. matologictoxicitiesresultedin9%ofcycleswithdosere-
duction and 21% delayed cycles. These results may be
DISCUSSION improved with a larger use of G-CSF because only three
patientsreceivedprophylacticG-CSF.Theothertoxicities
weremanageable,andnotoxicdeathsoccurred.
APAremainsanincurabledisease,andweeklygemcitabine
Because of a frequent desmoplastic reaction in APA,
has been widely adopted today as the standard of care in
tumorresponseassessmentisdifficult,especiallyinlocally
first-linechemotherapyforAPA,withmediansurvivallim-
advanceddisease.However,therewasnomajordifference
ited to the range of 4.6 to 6.6 months in randomized
betweentheinvestigatorsandtheERRCconclusions.The
studies.7-10,12,14,15,42-45MultivariateCoxregressionanalysis
encouragingresponserateof26%(CI95%,13%to39%)
identifiedprognosticfactorsforsurvival,mainlyPS,extent
with Folfirinox was similar in locally advanced disease
ofdisease(nonmetastaticvmetastatic),albuminlevel,lac-
(27.3%)andinmetastaticdisease(25.7%).Inourstudy,all
tatedehydrogenase,alkalinephosphatases,age,tumordif-
ferentiation, and appetite loss.7,43,44,46 Until now, no responseswereconfirmedbyasecondassessmentandwere
independently reviewed. Two CRs, a rare event in APA,
randomized trial has shown a significant QOL benefit or
overallsurvivalsuperiorityforanygemcitabine-basedcom- wereobserved(durationsof11and12months).Theoverall
bination over gemcitabine alone.7-15,43 Therefore, better response duration of 9.3 months (CI 95%, 8.2 to 13.6
systemictherapiesarewarranted. months) is also encouraging. The overall tumor growth
Inthisstudy,weofferedFolfirinoxforgoodPSpatients controlwas61%,withadurationof9.3months(CI95%,
(EasternCooperativeOncologyGroupPSof0and1).Pa- 7.8to11.7months).Althoughsecond-linechemotherapyis
tientswithKarnofskyPSlessthan70haveashortmedian oftenconsideredineffectiveinAPA,itwasofferedto67%of
survival(eg,2.4monthswhentreatedwithgemcitabine)47 patients,andonecannotcompletelyruleoutsomeclinical
andwerenoteligibleforthispotentiallytoxicregimen.In impactresultinginanimprovedsurvival.
www.jco.org 1233
Downloaded from jco.ascopubs.org on April 23, 2015. For personal use only. No other uses without permission.
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
Conroyetal
PatientQOLcanbegreatlyreducedbysideeffectsof de Recherche Clinique en Oncologie et Radiothérapie
chemotherapyorsymptomsofAPA,whichincludesevere (GERCOR)phaseIIstudywithafixeddose-rateinfusionof
pain,depression,weightloss,lossofappetite,andfatigue. gemcitabine1,000mg/m2asa10mg/m2/mininfusionon
QOL was measured in our study with the EORTC QLQ- day 1 and oxaliplatin 100 mg/m2 on day 2 every 2 weeks
C30.Asinallstudies,themajorproblemwithQOLassess- (Gemox). The response rate was 30.6%.49 Using 3-week
ment was the compliance, and eight questionnaires were Gemox schedule, the North Central Cancer Treatment
lackingatbaseline.However,theattritionratewaslow,and Group50hadaresponserateofonly10.9%.Thedifferences
attheendoftreatment,datawereavailableforallpatients intheseresultssuggestthatthemannerinwhichthedrugs
except two. All functional scales improved during treat- areadministeredinfluencestheregimen’sefficacy.Anon-
ment,exceptcognitivefunctioning.Thegreatestimprove- goingthree-armphaseIIIstudybytheEasternCooperative
mentinmedianscoreswasseenforrolefunctioning,social OncologyGroupwillbetterclarifyboththebenefitsofthe
functioning,andglobalQOL.Respondershadthegreatest fixeddose-rateinfusionofgemcitabineandtheaddedben-
improvement,withamedianimprovementof25pointsin efitofoxaliplatin.ArandomizedphaseIIIstudycomparing
globalQOL,whichisamajorchangeaccordingtoOsoba the GERCOR’s Gemox combination to standard weekly
criteria.41Themedianscoreoffatigueremainedstable,and gemcitabine was recently presented.11 Of 313 eligible pa-
pain, dyspnea, insomnia, appetite loss, and constipation tients, the response rate according the investigators was
were improved. The only item that deteriorated during 26.8%fortheGemoxcombinationversus17.3%forgem-
treatmentwasdiarrhea. citabine alone (P (cid:4) .02); PFS was 5.8 and 3.7 months,
Untilnow,fewstudieshavedemonstratedaQOLim- respectively(P(cid:4).038).However,nosignificantincreasein
provementwithchemotherapyinAPA.In1996,Glimelius survivalwasobserved,andQOLwasnotmeasured.
etal5reportedon53patientsrandomlyassignedtoreceive Inconclusion,theFolfirinoxregimenseemspromising
chemotherapy(FUandleucovorinwithorwithoutetopo- forgoodPSpatients.Theobjectiveresponseratewas26%,
side)plusBSCorBSCalone.ChangesinEORTCQLQ-C30 includingtwoCRs,andtumorcontrolwasachievedin61%
werecategorizedbytwoassessorswhowereunawareofthe ofpatients.Themediandurationofresponse(9.3months)
patientgroupassignment.Elevenpatients(38%)werecon- and the median survival (10.2 months) are encouraging.
sideredtohaveafavorableQOLoutcomeinthechemother- Toxicity,whichwasmainlyhematologic,wasmanageable,
apygroupcomparedwiththreepatients(13%)intheBSC and an improvement in almost all the EORTC QLQ-C30
group. However, the sample size was small, and the QOL QOLdomainswasobserved.Thisinvestigationalcombina-
evaluation was limited to the first 4 months. Most of the tionisnowtestedinanongoingphaseIItoIIItrialversus
furtherstudiesshowedarapiddegradationinQOLduring gemcitabineinpatientswithmetastaticpancreaticcancer.
chemotherapy, probably mostly because of tumor pro-
■ ■ ■
gression. In only one study, global QOL at 24 weeks was
significantlysuperiortothepretreatmentvaluewithaFU- Acknowledgment
mitomycin combination.46 The pain and dyspnea scores WethankChristineGayetforhermanagementofdata
were also improved. Two studies have formally assessed throughoutthestudyandLudovicMussakforhishelpful
QOLduringgemcitabinetreatment.Resultsarecontradic- contributiontothestatisticalanalysis.
tory,withimprovementofQOLinonestudy8andworsen-
ingofQOLat4and8weeksinanother.44 Authors’ Disclosures of Potential
Other trials have assessed irinotecan or oxaliplatin in Conflicts of Interest
APA. The combination of gemcitabine plus irinotecan is Thefollowingauthorsortheirimmediatefamilymem-
activeinAPA.48ArandomizedphaseIIIstudycomparing bershaveindicatedafinancialinterest.Noconflictexistsfor
gemcitabine alone to gemcitabine-irinotecan was recently drugsordevicesusedinastudyiftheyarenotbeingevalu-
published.12Theconfirmedresponseratewassignificantly atedaspartoftheinvestigation.Employment:Emmanuelle
betterinthetwo-drugregimenthanwithgemcitabinealone Magherini,Aventis;AlietteHua,Aventis.Consultant/Advi-
(16.1%v4.4%,respectively;P(cid:2).001).However,therewas soryRole:BernardPaillot,Aventis;EricFrancois,Aventis;
nodifferenceinPFS,overallsurvival,andQOL.Theefficacy GaelDeplanque,Aventis,Sanofi-Synthelabo.StockOwner-
ofoxaliplatinwastestedinathree-armrandomizedphaseII ship: Emmanuelle Magherini, Aventis. Honoraria: Gael
studycomparingoxaliplatin130mg/m2,FU1g/m2/dcon- Deplanque,Aventis,Sanofi-Synthelabo.Foradetailedde-
tinuousinfusionfor4days,andthetwodrugscombined; scriptionofthesecategories,orformoreinformationabout
the response rates were 0%, 0%, and 10% respectively. ASCO’sconflictofinterestpolicy,pleaserefertotheAuthor
Tolerance was excellent, and the median survival of 9 Disclosure Declaration and the Disclosures of Potential
months in the oxaliplatin-FU arm was encouraging.28 ConflictsofInterestsectionofInformationforContribu-
Sixty-two patients were treated in a Groupe d’Etude et torsfoundinthefrontofeveryissue.
1234 JOURNALOFCLINICALONCOLOGY
Downloaded from jco.ascopubs.org on April 23, 2015. For personal use only. No other uses without permission.
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
FolfirinoxinAdvancedPancreaticCancer
cancer(APC).JClinOncol22:315s,2004(suppl 29. Zeghari-SqualliN,RaymondE,CvitkovicE,
REFERENCES 14,abstr4006) etal:Cellularpharmacologyofthecombination
15. RichardsDA,KindlerHL,OettleH,etal:A oftheDNAtopoisomeraseIinhibitorSN-38and
1. Jemal A, Murray T, Samuels A, et al: randomizedphaseIIIstudycomparinggemcita- thediaminocyclohexaneplatinumderivativeox-
Cancerstatistics,2003.CACancerJClin53:5- bine (cid:5) pemetrexed versus gemcitabine in pa- aliplatin.ClinCancerRes5:1189-1196,1999
26,2003 tients with locally advanced and metastatic 30. GoldwasserF,BozecL,Zeghari-SqualliN,
2. FernandezE,La-VecchiaC,PortaM,etal: pancreas cancer. J Clin Oncol 22:315s, 2004 etal:Cellularpharmacologyofthecombination
TrendsinpancreaticcancermortalityinEurope, (suppl14,abstr4007) of oxaliplatin with topotecan in the IGROV-1
1955-1989.IntJCancer57:786-792,1994 16. MatsuokaH,YanoK,SeoY,etal:Cyto- humanovariancancercellline.AnticancerDrugs
3. SantM,AareleidT,BerrinoF,etal:EURO- toxicity of CPT-11 for gastrointestinal cancer 10:195-201,1999
CARE-3: Survival of cancer patients diagnosed cells cultured on fixed-contact-sensitive plates. 31. Ychou M, Conroy T, Seitz JF, et al: An
1990-94—Resultsandcommentary.AnnOncol
AnticancerDrugs6:413-418,1995 openphaseIstudyassessingthefeasibilityof
14:61-118,2003(suppl5)
17. Mullany S, Svingen PA, Kaufmann SH, thetriplecombination:Oxaliplatinplusirinotecan
4. Palmer KR, Kerr M, Knowles G, et al:
et al: Effect of adding the topoisomerase I plus leucovorin/5-fluorouracil every 2 weeks in
Chemotherapy prolongs survival in inoperable
poison7-ethyl-10-hydroxycamptothecin(SN-38)to patientswithadvancedsolidtumors.AnnOncol
pancreatic carcinoma. Br J Surg 81:882-885,
5-fluorouracilandfolinicacidinHCT-8cells:Ele- 14:481-489,2003
1994
vateddTTPpoolsandenhancedcytotoxicity.Can- 32. TournigandC,DeGramontA,LouvetC,et
5. GlimeliusB,HoffmanK,SjodenPO,etal:
cerChemotherPharmacol42:391-399,1998 al:Asimplifiedbi-monthlyregimenwithleucov-
Chemotherapyimprovessurvivalandqualityof
life in advanced pancreatic and biliary cancer. 18. Pavillard V, Formento P, Rostagno P, orin(LV)and5-fluorouracil(5FU)formetastatic
AnnOncol7:593-600,1996 et al: Combination of irinotecan (CPT11) and colorectal cancer (MCRC). Proc Am Soc Clin
6. BurrisAH,MooreMJ,AndersenJ,etal: 5-fluorouracilwithananalysisofcellulardeter- Oncol17:274a,1998(abstr1052)
Improvements in survival and clinical benefit minants of drug activity. Biochem Pharmacol 33. MillerAB,HoogstratenB,StaquetM,etal:
withgemcitabineasfirst-linetherapyforpatients 56:1315-1322,1998 Reporting results of cancer treatment. Cancer
with advanced pancreas cancer: A randomized 19. Mans DR, Grivicich I, Peters GJ, et al: 47:207-214,1981
Sequence-dependent growth inhibition and DNA
trial.JClinOncol15:2403-2413,1997 34. Caussanel JP, Levi F, Brienza S, et al:
damageformationbytheirinotecan-5-fluorouracil
7. Berlin JD, Catalano P, Thomas JP, et al: PhaseItrialof5-daycontinuousvenousinfusion
combinationinhumancoloncarcinomacelllines.
Phase III study of gemcitabine in combination ofoxaliplatinatcircadianrhythm-modulatedrate
EurJCancer35:1851-1861,1999
with fluorouracil versus gemcitabine alone in comparedwithconstantrate.JNatlCancerInst
20. Takeda S, Shimazoe T, Kuga H, et al:
patients with advanced pancreatic carcinoma: 82:1046-1050,1990
Camptothecinanalog(CPT-11)-sensitivehuman
Eastern Cooperative Oncology Group trial 35. AaronsonNK,AhmedzaiS,BergmanB,et
pancreatictumorcelllineQGP-1Nshowsresis-
E2297.JClinOncol20:3270-3275,2002 al:TheEuropeanOrganizationforResearchand
tancetoSN-38,anactivemetaboliteofCPT-11.
8. BramhallSR,SchulzJ,NemunaitisJ,etal: TreatmentofCancerQLQ-C30:Aquality-of-life
BiochemBiophysResCommun188:70-77,1992
A double-blind placebo-controlled, randomised instrumentforuseininternationalclinicaltrialsin
21. BisseryMC,VrignaudP,LavelleF,etal:
study comparing gemcitabine and marimastat oncology.JNatlCancerInst85:365-376,1993
Experimentalantitumoractivityandpharmacoki-
withgemcitabineandplaceboasfirstlinether- 36. Fayers P, Aaronson N, Bjordal K, et al:
netics of the camptothecin analog irinotecan
apyinpatientswithadvancedpancreaticcancer. EORTCQLQ-C30ScoringManual.Brussels,Bel-
(CPT-11) in mice. Anticancer Drugs 7:437-460,
BrJCancer87:161-167,2002 gium,EuropeanOrganisationforResearchand
1996
9. ColucciG,GiulaniF,GebbiaV,etal:Gem- TreatmentofCancer,1995
22. SakataY,ShimadaY,YoshinoM,etal:A
citabinealoneorwithcisplatinforthetreatment 37. Fayers P, Weeden S, Curran D: EORTC
latephaseIIstudyofCPT-11,irinotecanhydro-
of patients with locally advanced and/or meta- QLQ-C30ReferenceValues.Brussels,Belgium,
chloride, in patients with advanced pancreatic
staticpancreaticcarcinoma:Aprospective,ran- EuropeanOrganisationforResearchandTreat-
domizedphaseIIIstudyoftheGruppoOncologia cancer:CPT-11StudyGrouponGastroIntestinal ment of Cancer Quality of Life Study Group,
dell’ItaliaMeridionale.Cancer94:902-910,2002 Cancer. Gan To Kagaku Ryoho 21:1039-1046, 1998
10. HeinemannV,QuietzschD,GieselerF,et 1994 38. SimonR:OptimaltwostageforphaseII
al:AphaseIIItrialcomparinggemcitabineplus 23. WagenerDJ,VerdonkHE,DirixLY,etal:
clinicaltrials.ControlClinTrials10:1-10,1989
cisplatinvsgemcitabinealoneinadvancedpan- PhaseIItrialofCPT-11inpatientswithadvanced
creaticcarcinoma.ProcAmSocClinOncol22: pancreaticcancer,anEORTCearlyclinicaltrials 39. Kaplan EL, Meier P. Nonparametric esti-
250,2003(abstr1003) groupstudy.AnnOncol6:129-132,1995 mationfromincompleteobservations.JAmStat
11. Louvet C, Labianca R, Hammel P, et al: 24. Funakoshi A, Okusaka T, Ishii H, et al: Assoc53:457-481,1958
GemOx (gemcitabine (cid:5) oxaliplatin) versus Gem Phase II study of irinotecan (CPT-11) alone in 40. Shuster JJ: Median follow-up in clinical
(gemcitabine)innonresectablepancreaticadeno- patients(pts)withmetastaticpancreaticcancer. trials.JClinOncol9:191-192,1991
carcinoma:FinalresultsoftheGERCOR/GISCAD JClinOncol22:338s,2004(suppl14,abstr4102) 41. Osoba D, Rodrigues G, Myles J, et al:
intergroupphaseIII.JClinOncol22:315s,2004 25. Klapdor R, Fenner C: Irinotecan (Campto Interpreting the significance of changes in
(suppl14,abstr) R): Efficacy as third/fourth line therapy in ad- health-relatedqualityoflifescores.JClinOncol
12. RochaLimaCM,GreenMR,RotcheR,et vanced pancreatic cancer. Anticancer Res 20: 16:139-144,1998
al: Irinotecan plus gemcitabine results in no 5209-5212,2000 42. BramhallSR,RosemurgyA,BrownPD,et
survivaladvantagecomparedwithgemcitabine 26. Ulrich-PurH,RadererM,VerenaKornekG, al: Marimastat as first-line therapy for patients
monotherapyinpatientswithlocallyadvancedor et al: Irinotecan plus raltitrexed vs raltitrexed withunresectablepancreaticcancer:Arandom-
metastaticpancreaticcancerdespiteincreased alone in patients with gemcitabine-pretreated izedtrial.JClinOncol19:3447-3455,2001
tumorresponserate.JClinOncol22:3776-3783, advancedpancreaticadenocarcinoma.BrJCan- 43. VanCutsemE,vandeVeldeH,KarasekP,
2004 cer88:1180-1184,2003 etal:PhaseIIItrialofgemcitabineplustipifarnib
13. ScheithauerW,SchullB,Ulrich-PurH,et 27. Kornmann M, Fakler H, Butzer U, et al: comparedwithgemcitabineplusplaceboinad-
al:Biweeklyhigh-dosegemcitabinealoneorin Oxaliplatin exerts potent in vitro cytotoxicity in vancedpancreaticcancer.JClinOncol22:1430-
combination with capecitabine in patients with colorectal and pancreatic cancer cell lines and 1438,2004
metastatic pancreatic adenocarcinoma: A ran- livermetastases.AnticancerRes20:3259-3264, 44. Moore MJ, Hamm J, Dancey J, et al:
domised phase II trial. Ann Oncol 14:97-104, 2000 Comparison of gemcitabine versus the matrix
2003 28. Ducreux M, Mitry E, Ould-Kaci M, et al: metalloproteinase inhibitor BAY 12-9566 in pa-
14. O’ReillyEM,Abou-AlfaGK,LetourneauR, RandomizedphaseIIstudyevaluatingoxaliplatin tients with advanced or metastatic adenocarci-
et al: A randomized phase III trial of DX-8951f alone,oxaliplatincombinedwithinfusional5-FU, noma of the pancreas: A phase III trial of the
(exatecanmesylate;DX)andgemcitabine(GEM) andinfusional5-FUaloneinadvancedpancreatic NationalCancerInstituteofCanadaclinicaltrials
vs. gemcitabine alone in advanced pancreatic carcinomapatients.AnnOncol15:467-473,2004 group.JClinOncol21:3296-3302,2003
www.jco.org 1235
Downloaded from jco.ascopubs.org on April 23, 2015. For personal use only. No other uses without permission.
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
Conroyetal
45. Cheverton P, Friess H, Andras C, et al: 47. StornioloAM,EnasNH,BrownCA,etal: 49. LouvetCH,AndreT,LledoG,etal:Gem-
PhaseIIIresultsofexatecan(DX-8951f)versus Aninvestigationalnewdrugtreatmentprogram citabine combined with oxaliplatin in advanced
gemcitabine (Gem) in chemotherapy-na¨ıve pa- forpatientswithgemcitabine:Resultsforover pancreatic adenocarcinoma: Final results of a
tients with advanced pancreatic cancer (APA). 3000patientswithpancreaticcarcinoma.Cancer GERCORmulticenterphaseIIstudy.JClinOncol
JClinOncol22:314s,2004(suppl14,abstr4005) 85:1261-1268,1999 20:1512-1518,2002
46. Maisey N, Chau I, Cunningham D, et al: 48. RochaLimaCMS,SavareseD,BrucknerH, 50. AlbertsSR,TownleyPM,GoldbergRM,et
MulticenterrandomizedphaseIIItrialcomparing et al: Irinotecan plus gemcitabine induces both al: Gemcitabine and oxaliplatin for metastatic
protractedvenousinfusion(PVI)fluorouracil(5-FU) radiographicandCA19-9tumormarkerresponses pancreatic adenocarcinoma: A North Central
withPVI5-FUplusmitomycinininoperablepan- in patients with previously untreated advanced Cancer Treatment Group phase II study. Ann
creaticcancer.JClinOncol20:3130-3136,2002 pancreaticcancer.JClinOncol20:1182-1191,2002 Oncol14:580-585,2003
1236 JOURNALOFCLINICALONCOLOGY
Downloaded from jco.ascopubs.org on April 23, 2015. For personal use only. No other uses without permission.
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
